

Floxuridine

[View the current Floxuridine InDepth page on BioPortfolio.com \(PDF\)](#)

(<http://www.bioportfolio.com/indepth/Floxuridine.html>) - Regularly Updated.

Floxuridine is an oncology drug that belongs to the class known as antimetabolites. The drug is most often used in the treatment of colorectal cancer. ([From the Wikipedia article Floxuridine](#).)

Recent Publications on Floxuridine:



- [Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival.](#)
BACKGROUND: This study reports the results of hepatic arterial infusion... 10th November, 2009
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York,- *Ann Oncol.* 2009 Sep;20(9):1589-95. Epub 2009 Jun 2. ([DOI Direct Link](#))
- [Peroxisome proliferator-activated receptor gamma coactivator-1alpha enhances antiproliferative activity of 5'-deoxy-5-fluorouridine in cancer cells through induction of uridine phosphorylase.](#)
Peroxisome proliferator-activated receptor gamma coactivator-1alpha... 5th November, 2009
National Laboratory of Medical Molecular Biology, Institute of Basic- Mol Pharmacol. 2009 Oct;76(4):854-60. Epub 2009 Jul 14. ([DOI Direct Link](#))
- [Hepatic arterial infusion for unresectable colorectal liver metastases combined or not with systemic chemotherapy.](#)
BACKGROUND: The hypothesis was tested that systemic chemotherapy might... 23rd October, 2009
Clinica Chirurgica II, Department of Oncological and Surgical Sciences,- *Anticancer Res.* 2009 Oct;29(10):4139-44.
- [Substrate specificity of lipase from Burkholderia cepacia in the synthesis of 3'-arylaliphatic acid esters of floxuridine.](#)
Among the five vinyl esters bearing phenyl ring in acyl moiety, the lipase... 16th October, 2009
State Key Laboratory of Pulp and Paper Engineering, South China University- *J Biotechnol.* 2009 Jul 15;142(3-4):267-70. Epub 2009 Jun 17. ([DOI Direct Link](#))
- [Selective internal radiation therapy for liver metastases from colorectal cancer.](#)
BACKGROUND: Liver metastases are often the dominant site of metastatic... 13th October, 2009
The Queen Elizabeth Hospital, 28 Woodville Road,, Woodville, SA,- *Cochrane Database Syst Rev.* 2009 Oct 7;(4):CD007045. ([DOI Direct Link](#))
- [Postoperative chemotherapy after neoadjuvant chemoradiation and surgery for rectal cancer: is it essential for patients with ypT0-2N0?](#)
BACKGROUND: The potential advantage of adjuvant chemotherapy in patients... 9th October, 2009
Department of Surgery, Chonnam National University Hwasun Hospital and- *J Surg Oncol.* 2009 Oct 1;100(5):387-91. ([DOI Direct Link](#))
- [Development of a sensitive and selective LC-MS/MS method for simultaneous determination of gemcitabine and 2,2-difluoro-2-deoxyuridine in human plasma.](#)

- A sensitive, selective, and quantitative method for the simultaneous...* 9th October, 2009
Worldwide Bioanalysis and Systems Management, Preclinical Drug Metabolism- J Chromatogr B
Analyst Technol Biomed Life Sci. 2009 Jul 15;877(22):2123-9. ([DOI Direct Link](#))
- [Induction-concurrent chemoradiotherapy versus induction chemotherapy and radiotherapy for locoregionally advanced nasopharyngeal carcinoma.](#)
Background and Objective: Induction chemotherapy and radiotherapy or... 6th October, 2009
State Key Laboratory of Oncology in South China, Guangzhou, Guangdong,- Chin J Cancer. 2009 Oct;28(10):1033-42.
 - [Dose-response relationships of rat fetal skeleton variations: Relevance for risk assessment.](#)
In developmental toxicity studies, skeleton abnormalities found in fetuses... 2nd October, 2009
Institute of Clinical Pharmacology and Toxicology, Charite University- Environ Res. 2009 Oct;109(7):922-9. Epub 2009 Aug 13. ([DOI Direct Link](#))
 - [Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma.](#)
PURPOSE To determine the conversion to resectability in patients with... 17th September, 2009
Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell- J Clin Oncol. 2009 Jul 20;27(21):3465-71. Epub 2009 May 26. ([DOI Direct Link](#))
 - [Mass flows of X-ray contrast media and cytostatics in hospital wastewater.](#)
Little is known about the significance of hospitals as point sources for... 12th September, 2009
Eawag, Swiss Federal Institute of Aquatic Science and Technology, CH-8600- Environ Sci Technol. 2009 Jul 1;43(13):4810-7.
 - [The role of DNA damage response pathways in chromosome fragility in Fragile X syndrome.](#)
FRAXA is one of a number of fragile sites in human chromosomes that are... 26th August, 2009
Section on Gene Structure and Disease, Laboratory of Molecular and- Nucleic Acids Res. 2009 Jul;37(13):4385-92. Epub 2009 May 21. ([DOI Direct Link](#))
 - [Analysis of factors associated with outcome in patients undergoing isolated hepatic perfusion for unresectable liver metastases from colorectal center.](#)
AIM: To define the indications for hyperthermic isolated hepatic perfusion... 20th August, 2009
Department of Surgery, Greenebaum Cancer Center, University of Maryland- Ann Surg Oncol. 2009 Jul;16(7):1852-9. Epub 2009 May 12. ([DOI Direct Link](#))
 - [Fluoropyrimidine-HAI \(hepatic arterial infusion\) versus systemic chemotherapy \(SCT\) for unresectable liver metastases from colorectal cancer.](#)
BACKGROUND: Although locoregional treatments such as hepatic arterial... 15th August, 2009
Departement of Oncological & Surgical Sciences, University of Padova, Via- Cochrane Database Syst Rev. 2009 Jul 8;(3):CD007823. ([DOI Direct Link](#))
 - [\[Complete response obtained with first-line therapy as S-1, followed by second-line 5'-DFUR plus paclitaxel therapy in a patient with multiple liver and lymph node metastases from gastric cancer\]](#)
A 82-year-old man with advanced gastric cancer underwent distal... 13th June, 2009
Dept. of Surgery, Saga University Faculty of Medicine.- Gan To Kagaku Ryoho. 2009 May;36(5):851-4.

Floxuridine Patents:



- 7589125- [2,4-dihydroxybenzoic acid derivatives](#)
- 7598043- [Use of vascular endothelial growth factor receptor 1+ cells in treating and monitoring cancer](#)

[and in screening for chemotherapeutics](#)

- 7598052- [Expression profile of thyroid cancer](#)
- 7598261- [Spirocyclic heterocyclic derivatives and methods of their use](#)
- 7598348- [Adiponectin receptor variant, AdipoR2v2](#)
- 7598393- [Sulfonyl benzimidazole derivatives](#)
- 7601335- [Pretreatment of a biological sample from an autoimmune disease subject](#)
- 7601351- [Antibodies against protective antigen](#)
- 7601355- [Compositions and methods for altering immune function](#)
- 7601703- [Enzyme catalyzed therapeutic agents](#)
- 7601710- [Preparation of hymenialdisine derivatives and use thereof](#)
- 7598028- [Compositions and methods for detecting and treating prostate disorders](#)
- 7597886- [Tumor necrosis factor-gamma](#)
- 7597884- [Hyperglycosylated polypeptide variants and methods of use](#)
- 7589190- [Potent LNA oligonucleotides for the inhibition of HIF-1A expression](#)
- 7591844- [Medical devices, drug coatings and methods for maintaining the drug coatings thereon](#)
- 7592010- [Albumin fusion proteins](#)
- 7592016- [Methods for preparing and using implantable substance delivery devices](#)
- 7592342- [Quinoxaline derivatives as PI3 kinase inhibitors](#)
- 7592365- [Substituted pyrroles, compositions containing same, method for making same and use thereof](#)
- 7592422- [Modified plasminogen activator inhibitor type-1 and methods based thereon](#)
- 7595038- [Methods of treatment using antibodies to follistatin-3](#)
- 7595320- [Hydrazinocarbonyl-thieno\[2,3-C\]pyrazoles, process for preparing them, compositions containing them and use thereof](#)
- 7595379- [Antibodies and related molecules that bind to PSCA proteins](#)
- 7601724- [Substituted pyrazolo\[1,5-a\]pyrimidines as protein kinase inhibitors](#)
- 7604660- [Bifurcated medical appliance delivery apparatus and method](#)
- 7608699- [Synthetic nuclear localization signal derived from lentiviral integrase and methods of use thereof](#)
- 7611704- [Compositions and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids](#)
- 7612178- [Anti-IGF-1R antibodies and uses thereof](#)
- 7612180- [Humanized L243 antibodies](#)
- 7615208- [Metal ion-labeled bis-aminoethanethiol-targeting ligand conjugates, compositions, and methods for tissue-specific disease imaging](#)
- 7615209- [Compositions of NDV and methods of use thereof for treatment of cancer](#)
- 7615223- [Selected immunoconjugates for binding to aminophospholipids](#)
- 7615529- [Methods and compositions for modulating hyperstabilized c-met](#)
- 7615539- [Nucleic acid-lipophilic conjugates](#)
- 7615554- [Erastin and erastin binding proteins, and uses thereof](#)
- 7608643- [Compounds for inhibiting KSP kinesin activity](#)
- 7608635- [Pyrazole compounds that modulate HSP90 activity](#)
- 7608602- [Gemcitabine prodrugs, pharmaceutical compositions and uses thereof](#)
- 7604799- [EphA4 Antibodies](#)
- 7604947- [Detection and modulation of cancer stem cells](#)
- 7605138- [Nucleic acid compositions for stimulating immune responses](#)
- 7605144- [Enzyme catalyzed therapeutic compounds](#)
- 7605155- [Substituted pyrazolo\[1,5-a\]pyrimidines as protein kinase inhibitors](#)
- 7605175- [Inhibitors of cyclin-dependent kinases, compositions and uses related thereto](#)
- 7605236- [Antibodies that immunospecifically bind to B lymphocyte stimulator protein](#)
- 7608429- [Methods and compositions for increasing antibody production](#)
- 7608582- [Delivery vehicle comprising a modified MscL protein channel](#)
- 7608591- [Targeted delivery to legumain-expressing cells](#)

- 7618631- [Treatment with anti-ErbB2 antibodies and EGFR-targeted drugs](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

